干扰素双黄连雾化吸入治疗毛细支气管炎临床观察

Clinical observation on interferon and shuanghuanglian in bronchiolitis

目的:评价重组人干扰素α-2a联合双黄连注射液雾化吸入治疗毛细支气管炎的疗效及安全性。方法:选择毛细支气管炎82例,随机分为治疗组41例,除常规抗感染、对症、给氧等综合治疗外,加用重组人干扰素α-2a和双黄连注射液超声雾化吸入治疗;对照组41例,只采用常规治疗。临床观察喘息、气促、紫绀、肺部哮鸣音及痰鸣音好转情况、需人工吸痰次数及住院日。结果:治疗组患儿在喘息、气促、肺部伴症好转情况明显于对照组,需人工吸痰的次数明显减少,住院日缩短,经统计学检验差异有显著性(P<0.01)。结论:重组人干扰素α-2a双黄连超声雾化吸入治疗毛细支气管炎疗效明显。

Objective：To evaluate the curative effect and safety of recombination human interferon α-2a combined with shuanghuanglian injection in the nebulization treatment of bronchiolitis. Methods：82 patients with bronchiolitis selected from our in-patient department were randomly divided into two groups,with 41 cases in each group.The routine anti-infection,heteropathy,oxygen supply and so on were used in two groups,besides this,the treatment group was added with interferon and shuanghuanglian injection for aerosol inhalation. The clinical symptoms and signs,such as asthma,breathlessness,cyanosis,pulmonary wheezing and the improvement condition of wheezy phlegm as well as the times of artificial inhaling sputum and the days of hospitalization were observed respectively. Results：Compared with the control group,the condition of asthma,breathlessness and pulmonary symptom in the treatment was significant improvement,the times of artificial inhaling sputum were less and the days of hospitalization were short,with significant difference between two groups（P〈0.01）.Conclusion：The curative effect of recombination human interferon α-2a combined with shuanghuanglian in the nebulization treatment of bronchiolitis is obvious.